These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24955955)

  • 1. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
    Saini P; Li Y; Dobbelstein M
    Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.
    Chung S; Vail P; Witkiewicz AK; Knudsen ES
    Clin Cancer Res; 2019 Apr; 25(7):2290-2304. PubMed ID: 30538111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upgrading gemcitabine with recycled kinase inhibitors.
    Blanco FF; Pishvaian MJ; Brody JR
    Cell Cycle; 2014; 13(18):2810-1. PubMed ID: 25486467
    [No Abstract]   [Full Text] [Related]  

  • 12. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
    Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
    Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
    Koh SB; Wallez Y; Dunlop CR; Bernaldo de Quirós Fernández S; Bapiro TE; Richards FM; Jodrell DI
    Cancer Res; 2018 Jun; 78(11):3054-3066. PubMed ID: 29735549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
    Xiao Y; Ramiscal J; Kowanetz K; Del Nagro C; Malek S; Evangelista M; Blackwood E; Jackson PK; O'Brien T
    Mol Cancer Ther; 2013 Nov; 12(11):2285-95. PubMed ID: 24038068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
    Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.